Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E
First Department of Medicine, Hamamatsu University School of Medicine, Japan.
Clin Pharmacol Ther. 2001 Mar;69(3):158-68. doi: 10.1067/mcp.2001.113959.
Proton pump inhibitors such as omeprazole and lansoprazole are mainly metabolized by CYP2C19 in the liver. The therapeutic effects of proton pump inhibitors are assumed to depend on CYP2C19 genotype status.
We investigated whether CYP2C19 genotype status was related to eradication rates of H pylori by triple proton pump inhibitor-clarithromycin-amoxicillin (INN, amoxicilline) therapy and attempted to establish a strategy for treatment after failure to eradicate H pylori.
A total of 261 patients infected with H pylori completed initial treatment with 20 mg of omeprazole or 30 mg of lansoprazole twice a day, 200 mg of clarithromycin three times a day, and 500 mg of amoxicillin three times a day for 1 week. CYP2C19 genotypes of patients were determined with polymerase chain reaction-restriction fragment length polymorphism analysis. Patients without eradication after initial treatment were retreated with 30 mg of lansoprazole four times daily and 500 mg of amoxicillin four times daily for 2 weeks.
Eradication rates for H pylori were 72.7% (95% confidence interval, 64.4%-81.8%), 92.1% (confidence interval, 86.4%-97.3%), and 97.8% (confidence interval, 88.5%-99.9%) in the homozygous extensive, heterozygous extensive, and poor metabolizer groups, respectively. Thirty-four of 35 patients without eradication had an extensive metabolizer genotype of CYP2C19. Nineteen of those patients were infected with clarithromycin-resistant strains of H pylori. However, there were no amoxicillin-resistant strains of H pylori. Re-treatment of H pylori infection with dual high-dose lansoprazole-amoxicillin therapy succeeded in 30 of 31 patients with extensive metabolizer genotype of CYP2C19.
The majority of patients without initial eradication of H pylori had an extensive metabolizer CYP2C19 genotype but were successfully re-treated with high doses of lansoprazole and an antibiotic to which H pylori was sensitive, such as amoxicillin, even when the patients were infected with clarithromycin-resistant strains of H pylori.
质子泵抑制剂如奥美拉唑和兰索拉唑主要在肝脏中由CYP2C19代谢。质子泵抑制剂的治疗效果被认为取决于CYP2C19基因型状态。
我们研究了CYP2C19基因型状态是否与质子泵抑制剂-克拉霉素-阿莫西林三联疗法(国际非专利药品名称,阿莫西林)根除幽门螺杆菌的比率相关,并试图制定一种幽门螺杆菌根除失败后的治疗策略。
总共261例感染幽门螺杆菌的患者完成了初始治疗,每天两次服用20毫克奥美拉唑或30毫克兰索拉唑,每天三次服用200毫克克拉霉素,每天三次服用500毫克阿莫西林,持续1周。通过聚合酶链反应-限制性片段长度多态性分析确定患者的CYP2C19基因型。初始治疗后未根除的患者接受每天四次服用30毫克兰索拉唑和每天四次服用500毫克阿莫西林的再治疗,持续2周。
在纯合子广泛代谢型、杂合子广泛代谢型和慢代谢型组中,幽门螺杆菌的根除率分别为72.7%(95%置信区间,64.4%-81.8%)、92.1%(置信区间,86.4%-97.3%)和97.8%(置信区间,88.5%-99.9%)。35例未根除的患者中有34例具有CYP2C19的广泛代谢型基因型。其中19例患者感染了克拉霉素耐药的幽门螺杆菌菌株。然而,没有阿莫西林耐药的幽门螺杆菌菌株。对31例具有CYP2C19广泛代谢型基因型的患者采用高剂量兰索拉唑-阿莫西林双联疗法进行幽门螺杆菌感染再治疗,30例成功。
大多数初始未根除幽门螺杆菌的患者具有CYP2C19广泛代谢型基因型,但即使患者感染了克拉霉素耐药的幽门螺杆菌菌株,用高剂量兰索拉唑和一种幽门螺杆菌敏感的抗生素(如阿莫西林)进行再治疗仍取得成功。